SMC Update - February 2020
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Sodium zirconium cyclosilicate (Lokelma®) has been rejected for use in the treatment of hyperkalaemia in adult patients. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Update: Thanks to an observant reader (see comments below), I must clarify that NICE guidance exists that applies to England and Wales for this medicine which should be followed in those member countries.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - January 2020 | Drug Safety Update - February 2020 » |
Matthew,
I think you need to be careful with your standard statement "Routine use of rejected and restricted medicines should be avoided" as NICE has approved sodium zirconium cyclosilicate for use so here in England it has to be made available for persons meeting the criteria within the TA.
Thanks,
Andrew
Comment by Andrew Martin — February 11, 2020 #
@Andrew,
Thanks for pointing that out, NICE don't usually issue guidance before the SMC but it seems that I missed their Technology Appraisal in September. I'll update the post.
Comment by Matthew Robinson — February 11, 2020 #